Pages that link to "Q38642809"
Jump to navigation
Jump to search
The following pages link to Cristiano Noto (Q38642809):
Displaying 50 items.
- Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis (Q34674152) (← links)
- Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. (Q35179022) (← links)
- PRODH polymorphisms, cortical volumes and thickness in schizophrenia (Q37548891) (← links)
- Recognition of bipolar disorder type I before the first manic episode: challenges and developments. (Q38125216) (← links)
- Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies. (Q38133770) (← links)
- Targeting the inflammatory pathway as a therapeutic tool for major depression. (Q38189995) (← links)
- Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. (Q38449239) (← links)
- Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research (Q38454097) (← links)
- Determinants of adherence to treatment in first-episode psychosis: a comprehensive review (Q38462271) (← links)
- The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder (Q38582809) (← links)
- Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls (Q38920812) (← links)
- Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia (Q39110344) (← links)
- Changes in gene expression and methylation in the blood of patients with first-episode psychosis (Q39120786) (← links)
- Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naïve patients with first-episode psychosis (Q40420456) (← links)
- Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone (Q40675735) (← links)
- Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese. (Q41000405) (← links)
- Omics-based depression and inflammation research (Q46754159) (← links)
- Accessing Gene Expression in Treatment-Resistant Schizophrenia. (Q47551450) (← links)
- Leukocyte telomere length variation in different stages of schizophrenia (Q47581150) (← links)
- Shorter leukocyte telomere length in patients at ultra high risk for psychosis (Q47781439) (← links)
- Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version (Q47846672) (← links)
- New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage (Q47859767) (← links)
- Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. (Q47955421) (← links)
- Effects of depression on the cytokine profile in drug naïve first-episode psychosis. (Q48107320) (← links)
- Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. (Q48528979) (← links)
- Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls. (Q48788276) (← links)
- Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naïve patients with first-episode psychosis. (Q48855965) (← links)
- Hair cortisol in drug-naïve first-episode individuals with psychosis (Q48947277) (← links)
- What are the PANSS items most related with global improvements in patients with schizophrenia? Toward a reduced version of the PANSS. (Q50633836) (← links)
- Association of biomarkers and depressive symptoms in schizophrenia. (Q50781283) (← links)
- Structural covariance in schizophrenia and first-episode psychosis: An approach based on graph analysis. (Q50794320) (← links)
- Investigating brain structural patterns in first episode psychosis and schizophrenia using MRI and a machine learning approach. (Q51556686) (← links)
- Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls. (Q52149925) (← links)
- T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA. (Q54997250) (← links)
- O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS. (Q55199588) (← links)
- F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA. (Q55261526) (← links)
- Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder (Q57481517) (← links)
- Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort (Q58782266) (← links)
- Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment (Q60440083) (← links)
- Angiotensin converting enzyme activity is positively associated with IL-17a levels in patients with schizophrenia (Q60618724) (← links)
- High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance (Q60618725) (← links)
- Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis (Q60618727) (← links)
- Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis (Q62722210) (← links)
- Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages (Q64108342) (← links)
- Disorganized Symptoms Predicted Worse Functioning Outcome in Schizophrenia Patients with Established Illness (Q86821993) (← links)
- Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis (Q90867161) (← links)
- Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia (Q92280272) (← links)
- How challenging is to manage agitated patients? (Q92313604) (← links)
- Schneider's first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis (Q92538602) (← links)
- DGCR2 influences cortical thickness through a mechanism independent of schizophrenia pathogenesis (Q92556081) (← links)